Subsequently, following the findings of Keynote 048 trial, pembrolizumab received approval for use in combination with platinum and fluorouracil for all patients with HNSCC, and as a monotherapy for patients whose tumors express PD-L1 CPS ≥ 1 (82). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.